From new industry M&As to insights on how to recruit Gen Z talent, there’s plenty to discover in our latest pharma news round ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

AbbVie ABBV has been actively ramping up its deal-making efforts lately, thereby strengthening its pipeline. While immunology ...

(STAT News) How a dinner in Paris revived talks for Sanofi’s $9.5 billion deal for Blueprint Medicines. For Blueprint Medicines, a monumental meal in the City of Bridges helped bring back to life ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another.

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations ...

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines ...

Opinion: Lehigh Valley can’t afford tariffs on medicines Sue Miller, a quality control technician, tests samples Thursday, Feb. 10, 2022, at U.S. Specialty Formulations in Allentown.

18.3% of patients on Dupixent achieved sustained remission vs. 6.1% on placebo at 36 weeks. Median corticosteroid use was 2.8g with Dupixent vs. 4.1g with placebo in BP patients. Get ahead of Wall ...

The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine development by leveraging local health-tech ecosystems and research ...